Full Press Release Details
MN 221 may result in fewer cardiovascular side effects than the current standard of care 40 MediciNova, Inc. 2011 Since the average hospitalization cost is $6,477 in the US, the payor would save this amount for each hospitalization prevented. Since US hospitals lose money on the typical asthma hospitalization due to low reimbursements from Medicaid and HMOs, hospitals would also make more money for each asthma hospitalization prevented.
In summary, we have not seen clinically significant safety concerns with MN 221. According to interviews of emergency room physicians, less selective injectable beta agonists such as epinephrine and terbutaline are not commonly used to treat acute asthma. The main reason they are not used more often is due to safety concerns, particularly cardiovascular side effects.
Comparative study of the effects of acute asthma in relation to a recovered airway tree on airflow patterns. In: 13th International conference on Biomedical Engineering 2009 V. 23. ISBM 978 3 540 92841 6 (online) (3) University of California, San Diego, School of Medicine, Division of Medical Education https://meded.ucsd.edu/isp/1998/asthma/html/naep.html MediciNova, Inc. 2011 MediciNova has preclinical data and clinical data which demonstrates the safety of MN 221.
They have all cited the fact that if a patient is having difficulty breathing, the patient cannot fully inhale medicine. MN 221 may improve efficacy over current standard of care due to its route of administration 39 (1) Veen et al. Recurrent exacerbations in severe asthma are associated with enhanced airway closure during stable episodes. Am J Respir Crit Car Med 2000:161(6):1902 06) (2) Inthavong et al.
Chronic Mucus Plug Formation: In severe asthma, mucus secretion and the formation of inspissated mucus plugs can cause persistent airflow limitation (3). Taken together, delivery of aerosolized medications to the distal airways is negatively impacted during an acute asthma exacerbation. Anecdotal evidence The emergency room doctors in our studies and key opinion leaders we have spoken to all believe in the concept of intravenous beta 2 agonist to treat acute exacerbations of asthma.
The bronchoconstriction, inflammation, and mucus plugging that occur during an acute exacerbation of asthma will magnify this problem. Modeling of airflow patterns in patients with acute asthma demonstrates that airway resistance is twice as high during the exacerbation than after recovery. Furthermore, the airflow is more profoundly affected in regions where the effects of asthma are significant (2).
EDs annually 1 st line therapy in ED: Patients receive SOC, many while in the waiting room 2 nd line therapy in ED: Patients who do not initially respond continuing receiving SOC Large Market Opportunity for MN 221 1,500,000 1,500,000 Hospitalization: Patients who do not respond to SOC are eventually hospitalized Patients who respond to initial therapy and are discharged Patients who eventually respond to standard therapy and are discharged Source: CDC COPD surveillance in U.S. 2000; Expert interviews, team analysis MediciNova, Inc. 2011 Study Design Randomized, double blind, placebo controlled dose escalation study 48 subjects with stable moderate to severe Chronic Obstructive Pulmonary Disease (COPD) (FEV 1 30% 80% and FEV 1 /FVC ratio 0.7) at 6 sites Doses: 10 g/min for 15 minutes followed by 3.3 g/min for 45 minutes (1 hour infusion with a total dose of 300 g) or placebo 20 g/min for 15 minutes followed by 6.67 g/min for 45 minutes (1 hour infusion with a total dose of 600 g) or placebo 40 g/min for 15 minutes followed by 13.3 g/min for 45 minutes (1 hour infusion with a total dose of 1,200 g) or placebo Outcome measures descriptive statistics only FEV 1 , PK, safety MN 221 CL 010 (COPD) 32 MediciNova, Inc. 2011 MN 221 CL 010: Mean Change in FEV 1 33 Baseline: 50.31% Baseline: 46.7% Baseline: 46.6% Baseline: 47.9% p = 0.0012 p = 0.0147 Addendum MediciNova, Inc. 2011 Study Design Randomized, placebo controlled, double blind, dose escalation study 23 subjects with mild to moderate stable asthma (FEV 1 60% predicted) at 4 sites Patients are randomized to one of four different treatment groups (25% of patients on placebo for every dose level)* Each treatment sequence consist of placebo and escalating doses of MN 221 (5.25 g, 15.0 g, 52.5 g, 150 g, 240 g, 450 g, 900 g) over 15 minutes Primary endpoint mean change in FEV 1 (forced expiratory volume in 1 second) from baseline (start of infusion) to 15 minutes (end of infusion) Outcome measures inferential statistics FEV 1 , pharmacokinetic (PK), safety and tolerability MN 221 CL 004 35 MediciNova, Inc. 2011 MN 221 CL 004: Mean Change in FEV 1 36 MediciNova, Inc. 2011 Study Design Randomized, placebo controlled, single blind, dose rate escalation study 17 subjects with moderate to severe stable asthma (FEV 1 40%, but 75% predicted) at 4 sites Doses: 16 g/min for 15 minutes followed by 8 g/min for 105 minutes (2 hour infusion with a total dose of 1,080 g) or placebo 30 g/min for 15 minutes followed by 15 g/min for 45 minutes (1 hour infusion with a total dose of 1,125 g) or placebo Outcome measures descriptive statistics only FEV 1 , PK, safety MN 221 CL 005 37 MediciNova, Inc. 2011 MN 221 CL 005: Mean Change in FEV 1 38 Baseline: 64.6% Baseline: 69.4% 1 Hour: 82.0% 2 Hours: 81.5% Baseline: 68.6% Baseline: 68.6% 1 Hour: 70.5% 2 Hours: 71.2% MediciNova, Inc. 2011 Published evidence It has been demonstrated that airway abnormalities extend from the proximal to the most distal airways in asthmatics, and in severe stable asthmatics it has been postulated that one reason that they are difficult to control is that inhaled particle (drug) deposition in the distal airways is impaired (1).
Source: CDC, CDC COPD surveillance in U.S. 2000; US Census; American Lung Association website *For COPD pts. with anemia; for pts. w/o anemia the stay is ~5.8 days at a cost of ~$25K COPD Discharged Hospitalized 72% 28% 1,900 Asthma 52% 48% 1,500 Hospitalization rates amongst Asthma and COPD patients Thousands MediciNova, Inc. 2011 In patients who respond to theophylline: IV aminophylline (used rarely) Noninvasive intermittent ventilation (NIV) (e.g. bipap mask) Source: Global Initiative for Chronic Obstructive Lung Disease 2007; team analysis 30 Represents leading drugs currently used History and physical Pulse oximetry Arterial blood gas (ABG), Chest X ray (CXR) Other physical and clinical evaluation to assess severity Hospitalization and resumption of first line therapy ICU admission Intubation/ mechanical ventilation Resumption of first line therapy Initial assessment Standard treatments Other treatments (not commonly used) Initial treatment failure and subsequent hospitalization COPD: Current treatment paradigm in emergency department and hospital settings Hospitalized patients follow the same treatment paradigm as in ER COPD management in the hospital and ICU settings mirrors the ER approach There are few treatment options beyond the first line of therapy Concurrently: Low flow oxygen Intermittent or continuous nebulized short acting 2 agonist (SABA) (e.g., Albuterol) Nebulized anticholinergic (e.g., Ipratropium) IV or oral systemic steroids (e.g., Methyl prednisolone) Antibiotics MediciNova, Inc. 2011 31 COPD Exacerbation Treatment Flow in Emergency Departments in the U.S. 225,000 1,275,000 1,275,000 510,000 765,000 765,000 Input: 1,500,000 patients with acute exacerbations of asthma present at U.S.
Source: CDC, CDC COPD surveillance in U.S. 2000; US Census; American Lung Association website MediciNova, Inc. 2011 29 A COPD exacerbation is a sustained worsening of the patient's condition, from the stable state and beyond normal day to day variations, that is acute in onset. COPD exacerbations are associated with a significant increase in mortality, hospitalization and healthcare utilization. 1.5 million hospital emergency department visits 765,000 hospitalizations Average length of stay 7.4 days* Average cost ~$32,000* 119,000 deaths COPD Exacerbations COPD patients are generally more ill than asthmatics with overall higher hospitalizations and mortality.
COPD includes two main conditions: emphysema and chronic obstructive bronchitis. Cigarette smoking is the leading cause of COPD. An estimated 10 million adults had a diagnosis of COPD in the U.S. in the year 2000. The prevalence and age adjusted death rate for COPD increased more than 30 percent since 1980. The direct/indirect costs related to COPD amounted to approximately $42.6 billion in the U.S. in 2007.
Waxman Hatch grants 5 years of exclusivity from approval in the U.S. Exclusivity in Europe is 10 years for first approval of new chemical entities. MN 221 Potential Development Opportunity: Exacerbations of COPD MediciNova, Inc. 2011 28 Chronic Obstructive Pulmonary Disease Chronic obstructive pulmonary disease (COPD) is a progressive disease that causes airflow blockage and breathing related problems.
The U.S. patent for MN 221 has composition of matter and method of use claims and is set to expire no earlier than February 2017. U.S. patent expiration does not include Waxman Hatch patent term restoration (industry average = 4.5 years). Corresponding composition of matter patents in various other countries are set to expire no earlier than February 2017.
Anticipated completion in 2H, 2011* MN 221 CL 007: Study Design 24 Note: Development plans / timelines for MN 221 clinical trials are subject to change *Anticipated completion date based on current projections MediciNova, Inc. 2011 MN 221 Safety Summary Safety Database: MN 221 has been tested in almost 300 subjects in the US and Europe to date No serious adverse events related to MN 221 were reported in any studies completed to date No clinically significant cardiovascular, ECG, or vital sign changes, or other safety concerns have been reported Doses up to 3,840 micrograms have been tested at different infusion rates Subjects tested have included healthy volunteers, healthy pregnant women, and asthmatics 25 MediciNova, Inc. 2011 MN 221 Patent Summary 26 MediciNova has rights to a portfolio of patents and know how related to MN 221, including composition of matter.
MediciNova, Inc. 2011 Randomized, placebo controlled, double blind, multi center Phase II clinical trial Up to 200 patients with severe, acute exacerbations of asthma (FEV 1 50% predicted) at multiple Emergency Department sites in the United States Dose Groups (up to 100 patients/group): 1,200 g of MN 221 over 1 hour (600 g in 15 minutes; 600 g in next 45 minutes) Placebo Patients will receive SOC treatment in addition to adjunctive treatment with MN 221 or placebo Primary efficacy endpoint will be improvement in FEV 1 (% predicted) at 3 hours The study is designed to have 80% power to detect a treatment difference of 5 percentage points in FEV 1 (% predicted) when comparing MN 221 + SOC to Placebo + SOC at a two sided level of 0.05.
There were no safety concerns with adding MN 221 to the standard of care. There was a reduction in the hospitalization rate among patients treated with MN 221. Overall, improvement in FEV 1 was greater for patients receiving MN 221 than placebo. A dose of 1,200 g of MN 221 administered over one hour was selected for the MN 221 CL 007 trial. MN 221 CL 006: What have we learned?
Randomized, placebo controlled, single blind, dose escalation study 29 patients with acute exacerbations of asthma (FEV 1 55% predicted) at 8 Emergency Department sites Doses: 16 g/min for 15 minutes (240 g) 30 g/min for 15 minutes (450 g) 16 g/min for 15 minutes; 8 g/min for 105 minutes (1,080 g) Patients received Standard of Care (SOC) treatment in addition to adjunctive treatment with MN 221 or placebo Outcome measures descriptive statistics only FEV 1 , PK, safety MN 221 CL 006: Study Design 21 MediciNova, Inc. 2011 MN 221 CL 006 Mean Change in FEV 1 and Differences in Hospitalization Rate 22 Mean change in FEV 1 from baseline was 5.3% higher in the MN 221 dose groups versus the placebo group MN 221 reduced the hospitalization rate by 45% MediciNova, Inc. 2011 23 What did we learn from MN 221 CL 006?
Reduced Health Care Expenses 18 MN 221: A New Approach to Treating Acute Exacerbations of Asthma MediciNova, Inc. 2011 Beta 2 agonist U.S. Market Overview 19 MediciNova, Inc. 2011 MN 221 Phase II Study Designs in Asthma Indication 20 MN 221 CL 004 MN 221 CL 005 MN 221 CL 006 MN 221 CL 007 Type of Asthma Stable mild to moderate Stable moderate to severe Acute Exacerbations Acute Exacerbations FEV 1 (Entry Criteria) FEV 1 60% 40% FEV 1 75% FEV 1 55% FEV 1 50% Number Patients 23 17 29 200 projected Number Sites 4 4 8 20 projected Doses compared to Placebo 5.25, 15, 52.5, 150, 240, 450, 900 g over 15 min 1080 g over 2 hr; 1,125 g over 1 hr 240, 450 g over 15 min; 1080 g over 2 hr 1200 g over 1 hr Concurrent Therapy None None Standard of care Standard of care MediciNova, Inc. 2011 Completed Phase IIa trial in the Emergency Dept.
Reduces the hospitalization rate among patients treated with MN 221. No clinical adverse effects when added to standard of care. MediciNova, Inc. 2011 MN 221: A novel, highly selective 2 adrenergic receptor agonist Three potential advantages over current therapy: 1. Improved Efficacy Route of Administration (IV v. Inhalation) 2. Improved Safety Higher selectivity for 2 receptor than 1 Partial agonist for 1 receptor 3.
It is administered adjunctive to standard of care by intravenous infusion. A well tolerated, potent, selective 2 agonist which is only a partial agonist at 1 . A bronchodilating duration of action that is longer than Short Acting Beta Agonists (SABAs) and shorter than Long Acting Beta Agonists (LABAs). Provides additional bronchodilation when used in addition to the standard treatments of inhaled albuterol, inhaled ipratropium, and steroids.
Limitations of Inhaled Therapies: Bronchoconstriction : inflammation and bronchoconstriction result in insufficient air flow to get good drug deposition in the lungs Mucus Plug Formation : mucus secretion and the formation of thick mucus plugs can cause persistent airflow limitation Albuterol Non Responders : not all patients benefit from albuterol Limitations of Current Intravenous Therapies: Safety : currently available options (e.g. epinephrine, terbutaline) have significant cardiovascular risks at doses used MediciNova, Inc. 2011 17 MN 221: Target Product Profile MN 221 Indication: Treatment of bronchospasms in patients with acute exacerbations of asthma or COPD.
EDs annually 1 st line therapy in ED: Patients receive SOC, many while in the waiting room 2 nd line therapy in ED: Patients who do not initially respond continuing receiving SOC Large Market Opportunity for MN 221 1,900,000 1,900,000 Hospitalization: Patients who do not respond to SOC are eventually hospitalized Patients who respond to initial therapy and are discharged Patients who eventually respond to standard therapy and are discharged Source: Weber, Silverman et al, American Journal of Medicine, 2002, Volume 113; pp 371 MediciNova, Inc. 2011 16 Limitations of Current Therapies What are the limitations of current therapies for acute exacerbations of asthma?
Shared Risk 2. All indications; Ibudilast + Analogues 3. Option Agreement around Phase 2b Diabetic Peripheral Neuropathic Pain and/or Progressive MS trial with Exclusive License, Development Milestones, Royalties, Sales Milestones. Sustain NIDA sponsored Drug Addiction development Consider Investigator sponsored Neurological Trials 12 Most Likely Scenario for Ibudilast s Development MN 221: Acute Exacerbations of Asthma Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) MediciNova, Inc. 2011 14 Acute Exacerbations of Asthma Definition: Long lasting and severe asthma episode that is not responsive to initial bronchodilator or corticosteroid therapy Market Opportunity*: Approximately 2 million annual emergency room visits in the US ~500,000 annual hospitalizations in the US Average length of stay for asthma hospitalization is 3.3 days Average cost for asthma hospitalization is $6,477 Approximately 2.7 million annual emergency room visits in UK/Spain/Germany/France/Italy ~560,000 annual hospitalizations in UK/Spain/Germany/France/Italy Current Standard of Care (SOC): Inhaled Beta agonists, inhaled anticholinergics, and IV or oral corticosteroids *Source: National Center for Health Statistics / CDC, WHO website, Core Health indicators , 2007 National Hospital Discharge Survey, IMS Health s Disease and Condition Benchmarks PharMetrics Integrated Database, 1/2007 12/2008 MediciNova, Inc. 2011 15 Acute Asthma Treatment Flow in Emergency Departments (EDs) in the U.S. 965,000 935,000 935,000 410,000 525,000 525,000 Input: 1,900,000 patients with acute exacerbations of asthma present at U.S.
Secured $15M Debt Financing from Oxford Finance Corporation on May 10, 2010 4. Announced Positive Safety and Efficacy data for Ibudilast (MN 166/AV411) Phase Ib/2a Study Results for Opioid Withdrawal and Analgesia on December 13, 2010 Investment Highlights *Anticipated completion dates based on current projections Ibudilast: Neuropathic Pain Multiple Sclerosis Addiction MediciNova, Inc. 2011 8 Ibudilast (MN 166/AV411) Oral administration Safe and well tolerated (approved in Japan/Korea with over 3.2 million patient exposures) Mechanism(s) of Action primarily Inhibition of Macrophage Migration Inhibitor Factor (MIF), PDE 4,10 inhibition; Attenuation of Glial Cell Activation Clinical Safety Preliminary Efficacy Completed Phase 2 Multiple Sclerosis Proof of Concept study (30 and 60 mg/d, predominately RRMS pts.) Completed Phase 1b/2a trial in Diabetic Neuropathic Pain (40 and 80 mg/d) Completed Phase 1b/2a clinical trial in Opioid Withdrawal Analgesia (40 and 80 mg/d) (Columbia Univ/NYSPI via NIDA funding) Ongoing Phase 1b Methamphetamine interaction trial (UCLA via NIDA funding) Additional Supporting Data 3 completed Phase 1 clinical trials Dosing up to 100 mg single dose 100 mg daily (50 mg twice/day) ~400 subjects treated with MN 166/AV411 to date (safe well tolerated) Ibudilast for the Treatment of MS, Neuropathic Pain, Drug Addiction MediciNova, Inc. 2011 9 Status for Chronic Pain: MN 166/AV411 is enabled to go directly to Phase 2b clinical development MN 166/AV411 mechanism of action is novel and thus complimentary to current pain treatments, and has both stand alone and adjunctive utilities Majority of potential pharma partners are strategically committed to new pain therapies MN 166/AV411 has an attractive development timeline and long term exclusivity Status for Drug Addiction/Opioid Withdrawal: Announced positive safety/efficacy results from Phase 1b/2a study in Opioid Withdrawal (12/10) UCLA initiated Phase Ib study for Methamphetamine Addiction (9/10) Status for Multiple Sclerosis: MN 166/AV411 requires significant funding for future trials Phase 2 data were at doses that are below maximum utility Most attractive option may be Progressive MS which would require an additional Phase 2b clinical trial Ibudilast (MN 166/AV411): Status for Each Indication MediciNova, Inc. 2011 10 Ibudilast Neuropathic Pain Market Opportunity Drug Company Total Rxs in 2009 (US) Lyrica Pfizer 9.1 Million Cymbalta Eli Lilly 14.7 Million Neurontin (Gabapentin) Pfizer 23.4 Million Total 47.1 Million Neuropathic Pain Annual Market Opportunity: ~$8.0 Billion Prevalence is approximately 4.2 million neuropathic pain patients in the U.S. and 40 million worldwide MN 166 has a different mechanism of action than currently marketed neuropathic pain therapies MN 166 has potential to capture substantial market share in the neuropathic pain market *Source: SDI/Verispan, Lilly and Pfizer Quarterly Reports Approved indications: Lyrica: Neuropathic pain associated with diabetic peripheral neuropathy, post herpetic neuralgia, partial onset seizures, fibromyalgia; Neurontin: postherpetic neuralgia, partial seizures ; Cymbalta: Major Depressive Disorder, Generalized Anxiety Disorder, Diabetic Peripheral Neuropathic Pain, Fibromyalgia Market Value Calculated at Branded Prices MediciNova, Inc. 2011 11 Patent/Commercial Overview Method of Use Composition of Matter MediciNova, Inc. 2011 Collaboration Structure with Pharma Partner: 1.
Secure a global partnership for Ibudilast (MN 166/AV411) 2. Secure a strategic partnership for MN 221 Upcoming Clinical Milestones: 1. MN 221 CL 007 Phase II Study for Acute Exacerbations of Asthma Anticipated completion in 2H, 2011* Completed Milestones in 2010: 1. Announced Positive MN 221 CL 010 Phase Ib Study Results in Moderate to Severe COPD Patients on March 17, 2010 3.
Kirk Johnson, Ph.D. Chief Scientific Officer 21 Avigen, Genesoft Pharmaceuticals, Chiron Corporation Masatsune Masatsune Okajima, CMA Okajima , CMA , CMA VP, Head of Japanese Office 19 Daiwa Securities SMBC, Sumitomo Capital Securities, Sumitomo Bank Management Team with Global Experience MediciNova, Inc. 2011 6 Upcoming Near Term Business Milestones: 1.
Continue internal development of compound towards commercialization 2. Seek partnership for further development of compound Business Model: Return On Investment MediciNova, Inc. 2011 5 Leadership Years Experience Background Yuichi Iwaki, MD, PhD Yuichi Iwaki, MD, PhD CEO President 35 Professor at USC, formerly Professor at University of Pittsburgh; Advisor to JAFCO, Tanabe Michael Coffee Michael Coffee Chief Business Officer; Interim Chief Financial Officer 26 Avigen, Amarin Corp., Elan Pharmaceuticals, N.A., Athena Neurosciences Kirk Johnson, Ph.D.
You are cautioned not to place undue reliance on these forward looking statements, which speak only as of February 1, 2011. MediciNova disclaims any intent or obligation to revise or update these forward looking statements. Forward Looking Statements MediciNova, Inc. 2011 3 MediciNova Overview: Founded in September 2000 Headquartered in San Diego, CA Additional office in Tokyo, Japan Dual listing on NasdaqGM as MNOV and Osaka Securities Exchange as 4875 $62.2 million Market Cap (NasdaqGM) as of 2/01/2011 Development Company Focused on Differentiated Product Candidates Unique access to differentiated, potentially high value assets primarily from Japanese alliances (Kyorin, Kissei, Mitsubishi Tanabe Pharma, Meiji) New Approaches to Treat Serious Medical Conditions: MN 221: Intravenous (IV) acute asthma and COPD candidate Potential $1 billion+ combined market opportunity worldwide* Ibudilast: Neuropathic pain, progressive multiple sclerosis, drug addiction candidate Corporate Overview: MediciNova, Inc. *Source: Internal MediciNova projections MediciNova, Inc. 2011 4 In License: Novel, small molecule product candidates with significant clinical or preclinical data packages and attractive market opportunities Conduct Proof of Concept Clinical Trials: Conduct Phase I and Phase II clinical trials to demonstrate safety and efficacy of compound Two Pathways After Phase II: 1.
These forward looking statements may be preceded by, followed by or otherwise include the words believes, expects, anticipates, intends, estimates, projects, can, could, may, will, would, or similar expressions. Actual results or events may differ materially from those expressed or implied in any forward looking statements due to various factors, including the risks and uncertainties inherent in clinical trials and product development and commercialization, such as the uncertainty in results of clinical trials for product candidates, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials and the timing, cost and design of future clinical trials and research activities; the timing of expected filings with the FDA; MediciNova s failure to execute strategic plans or strategies successfully; MediciNova s collaborations with third parties; MediciNova s ability to realize the anticipated strategic and financial benefits from its acquisition of Avigen, Inc., to integrate the two ibudilast development programs and to pursue discussions with potential partners to secure a strategic collaboration to advance the clinical development of the combined development program; the availability of funds to complete product development plans and MediciNova s ability to raise sufficient capital when needed, or at all; MediciNova s ability to comply with the covenants in its financing agreements; intellectual property or contract rights; and the other risks and uncertainties described in MediciNova s filings with the Securities and Exchange Commission, including MediciNova s annual report on Form 10 K for the year ended December 31, 2009 and its subsequent periodic reports on Forms 10 Q and 8 K.
These forward looking statements include statements regarding MediciNova s clinical trials supporting the safety and efficacy of its product candidates and the potential novelty of such product candidates as treatments for disease, plans and objectives for clinical trials and product development, strategies, future performance, expectations, assumptions, financial condition, liquidity and capital resources.
MediciNova, Inc. 2011 Accelerating the global development and commercialization of innovative pharmaceuticals Exhibit 99.1 MediciNova, Inc. 2011 Statements in this presentation that are not historical in nature constitute forward looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
MN 221 may reduce health care expenses by reducing the hospitalization rate 41 MediciNova, Inc. 2011 42 Commercially Attractive Diversified Portfolio COPD COPD Asthma Asthma Pain/MS Pain/MS Addiction Addiction